Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhou, Juan ^a   Ye, Yuanxin ^a   Zeng, Shugen ^a   Zhou, Yi ^a   Mao, Zhigang ^a   Song, Xingbo ^a   Ying, Binwu ^a   Lu, Xiaojun ^a   Jiang, Hong ^a   Wang, Lanlan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ADULT; ARTICLE; CELLULAR PARAMETERS; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE COUNT; FEMALE; FLUORESCENCE ANALYSIS; GENE FREQUENCY; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; HYPERPLASIA; JANUS KINASE 2 GENE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUTATION RATE; MUTATIONAL ANALYSIS; PATIENT ASSESSMENT; PLATELET DISTRIBUTION WIDTH; PLATELET LARGE CONTRAST RATIO; POLYCYTHEMIA VERA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; THROMBOCYTOPENIA;

ALLELES; FEMALE; HUMANS; HYPERPLASIA; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PLATELET COUNT; RETROSPECTIVE STUDIES;

EID: 84874566949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057856     Document Type: Article

References (38)

1. Kaushansky K (2009) Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program: 147-52.
2. Cervantes F, (2011) Management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2011: 215-21.
3. Skoda RC (2009) Thrombocytosis. Hematology Am Soc Hematol Educ Program: 159-67.
4. Chang CC, (2006) BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond. Arch Pathol Lab Med 130: 1123-5.
5. Calzada AA, Pedrini O, Finazzi G, Leoni F, Mascagni P, et al. (2012) Givinostat and Hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2 V617FMyeloproliferative Neoplasm patients. Exp Hematol. [Epub ahead of print].
6. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S, (2012) Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potentialof Janus kinase 2 inhibitors. J Hematol Oncol. 5: 43.
7. Santos FP, Verstovsek S (2012) Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am. [Epub ahead of print].
8. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-61.
9. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779-90.
10. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-8.
11. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera,essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-97.
12. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, et al. (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106: 3370-3.
13. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, et al. (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-8.
14. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W, (2005) A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 11: 546-54.
15. Hsu HC, (2007) Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders. J Chin Med Assoc 70: 89-93.
16. Saharinen P, Vihinen M, Silvennoinen O, (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14: 1448-59.
17. Garçon L, Rivat C, James C, Lacout C, Camara-Clayette V, et al. (2006) Constitutive activation of STAT5 and Bcl-xL overexpression can induceendogenous erythroid colony formation in human primary cells. Blood 108: 1551-4.
18. Silva M, Richard C, Benito A, Sanz C, Olalla I, et al. (1998) Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 338: 564-71.
19. Sokołowska B, Nowaczyńska A, Bykowska K, Chocholska S, Wejksza K, et al. (2011) JAK2 mutation status, hemostatic risk factors and thrombophilic factors inessential thrombocythemia (ET) patients. Folia Histochem Cytobiol 49: 267-71.
20. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, et al. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366: 1945-53.
21. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, et al. (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19: 1847-9.
22. Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, et al. (2009) Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology 14: 323-30.
23. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Jou JM, et al. (2012) Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia. Platelets. 23(5): 336-43.
24. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, et al. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111: 3931-40.
25. Godfrey AL, Green AR, (2012) Genotype-phenotype interactions in the myeloproliferative neoplasms. Hematol Oncol Clin North Am. 26(5): 993-1015.
26. James C (2008) The JAK2 V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematology Am Soc Hematol Educ Program: 69-75.
27. Tefferi A, Gilliland DG, (2005) The JAK2 V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 80: 947-58.
28. Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, et al. (2011) Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 90: 933-8.
29. Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, et al. (2011) JAK2 V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 118(9): 2599-601.
30. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, et al. (2005) Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood inmyeloproliferative disorders. Blood 107: 3676-82.
31. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, et al. (2006) The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108: 1865-7.
32. Lasho TL, Mesa R, Gilliland DG, Tefferi A, (2005) Mutation studies in CD3+, CD19+ and CD34+ cell fractions inmyeloproliferative disorders with homozygous JAK2(V617F) ingranulocytes. Br J Haematol 130: 797-9.
33. Hermouet S, Dobo I, Lippert E, Boursier MC, Ergand L, et al. (2007) Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F). Leukemia 21: 1128-30.
34. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, et al. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 110(3): 840-6.
35. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, et al. (2010) Conditional expression of heterozygous or homozygous JAK2 V617F from its endogenous promoter induces a polycythemia vera-like disease. 115(17): 3589-97.
36. Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A, (2012) Clinical significance of the quantification of JAK2 V617F allele burden in classical Ph-negative myeloproliferative neoplasms. Med Clin (Barc). 139(9): 373-8.
37. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, et al. (2012). Development and validation of an International Prognostic Score of thrombosis in WHO-Essential Thrombocythemia (IPSET-thrombosis). Blood. [Epub ahead of print].
38. Finazzi G, (2012) How to manage essential thrombocythemia. Leukemia. 26(5): 875-82.